De-cancer / curatio / medicinae / melanoma

Medicamenta Approbata pro Carcinoma

Haec pagina lists cancer medicinae probatus fuerit per Quod Cibus et medicamentis Administration (FDA) pro melanoma. Album quod includit nomina generica et torris nomen. Quod pharmacum est scriptor nomina NCI ad cancer summaria medicamentis Information. Medicinae non sit in melanoma, quae non enumerantur hic.

Medicamenta Approbata pro Carcinoma

Aldesleukin

Binimetinib

Braftovi (Encorafenib)

Cobimetinib

Cotellic (Cobimetinib)

Dabrafenib Mesylate

Dacarbazine

Encorafenib

II-II (Aldesleukin)

Imlygic (Talimogene Laherparepvec)

Interleuquina-II (Aldesleukin)

A Intrón (recombinante Interferón alfa-2a)

Ipilimumab

Keytruda (Pembrolizumab)

Mekinist (Trametinib)

Mektovi (Binimetinib)

Nivolumab

Opdivo (Nivolumab)

Alfa-2a Peginterferon

Polyquaternium, Intrón (Peginterferon alfa-2a)

Pembrolizumab

Proleukin (Aldesleukin)

Recombinante alfa-2a Interferón

Sylatron (Peginterferon alfa-2a)

Tafinlar (Dabrafenib Mesylate)

Talimogene Laherparepvec

Trametinib

Vemurafenib

Yervoy (Ipilimumab)

Zelboraf (Vemurafenib)